Glucagon-like peptide-1 receptor agonists improve metabolic dysfunction-associated steatotic liver disease outcomes

Glucagon-like peptide-1 receptor agonists improve metabolic dysfunction-associated steatotic liver disease outcomes

Abstract Metabolic dysfunction-associated steatotic liver disease (MASLD) is the leading cause of chronic liver disease and is associated with significant cardiovascular morbidity and mortality. This study aims to investigate the association of glucagon-like peptide-1 (GLP-1) agonists with major car...

Full description

Bibliographic Details
Main Authors: Brandon Havranek, Rebecca Loh, Beatriz Torre, Rachel Redfield, Dina Halegoua-DeMarzio
Format: Article
Language:English
Published: Nature Portfolio 2025-02-01
Series:Scientific Reports
Subjects:
Glucagon-like peptide-1 (GLP-1) receptor agonists
Metabolic dysfunction-associated steatotic liver disease (MASLD)
Cardiovascular risk
Portal hypertension
Nonalcoholic fatty liver disease (NAFLD)
Liver disease
Online Access:https://doi.org/10.1038/s41598-025-89408-z

Internet

https://doi.org/10.1038/s41598-025-89408-z

Similar Items